VRTX · News · 20260804N

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 71 · Surprise 60 · In source text

Vertex agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing approximately $10.0 billion of transaction value, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, subject to regulatory and Crinetics stockholder approvals. Vertex’s CEO highlighted two principal Crinetics assets that are projected to generate more than $5 billion in combined annual revenue. The transaction is intended to diversify Vertex’s therapeutic portfolio, particularly in endocrine and related disease areas.

Key facts

• Vertex announced a planned acquisition of Crinetics Pharmaceuticals for approximately $10.0 billion to further expand its therapeutic portfolio. source
• Crinetics agreed to be acquired by Vertex for $85.00 per share in cash, totaling approximately $10.0 billion. source
• The Crinetics acquisition value is approximately $8.8 billion net of estimated cash acquired. source
• Vertex's CEO said the two main assets acquired from Crinetics are projected to generate over $5 billion in combined annual revenue. source
• The Crinetics acquisition is expected to close in the third quarter of 2026, pending regulatory and stockholder approvals. source
• Crinetics Pharmaceuticals' stock hit an all-time high of $84.01, representing a 187.21% increase over the past year and a market capitalization of $8.85 billion. source
• TD Cowen said Vertex anticipates closing the CRNX acquisition in Q3. source

Impact estimates